# Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant For Hematological Cancer

> **NCT00589563** · PHASE2 · COMPLETED · sponsor: **City of Hope Medical Center** · enrollment: 32 (actual)

## Conditions studied

- Chronic Myeloproliferative Disorders
- Graft Versus Host Disease
- Infection
- Leukemia
- Lymphoma
- Multiple Myeloma and Plasma Cell Neoplasm
- Myelodysplastic Syndromes
- Myelodysplastic/Myeloproliferative Neoplasms
- Precancerous Condition
- Secondary Myelofibrosis
- Small Intestine Cancer

## Interventions

- **BIOLOGICAL:** anti-thymocyte globulin
- **DRUG:** cyclophosphamide
- **DRUG:** etoposide
- **DRUG:** fludarabine phosphate
- **DRUG:** melphalan
- **DRUG:** methotrexate
- **DRUG:** sirolimus
- **DRUG:** tacrolimus
- **PROCEDURE:** allogeneic hematopoietic stem cell transplantation
- **PROCEDURE:** hematopoietic stem cell transplantation
- **PROCEDURE:** nonmyeloablative allogeneic hematopoietic stem cell transplantation
- **PROCEDURE:** peripheral blood stem cell transplantation
- **RADIATION:** total-body irradiation

## Key facts

- **NCT ID:** NCT00589563
- **Lead sponsor:** City of Hope Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-05
- **Primary completion:** 2012-02
- **Final completion:** 2012-02
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2014-09-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00589563

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00589563, "Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant For Hematological Cancer". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT00589563. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*